
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery

- Telix's TLX599-CDx to be evaluated with Lightpoint's SENSEI[®], the world's first approved robotic gamma probe.
- When paired with molecularly-targeted imaging, SENSEI[®] enables the intra-operative detection of cancer in real time, supporting greater precision in the removal of tumours.
- Aim to advance new technology and transform treatment options in the fast-growing, high-value field of precision-guided cancer surgery (estimated addressable market US\$3B).

Melbourne (Australia) – 23 August 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has signed a strategic collaboration agreement with UK-based Lightpoint Medical ('Lightpoint'), a leading medical device company developing cancer detection tools for minimally-invasive and robot-assisted surgery. Under the collaboration the two companies will explore how Telix and Lightpoint technologies may be used together for radioguided surgery (RGS) to detect cancer in real-time.

Lightpoint has developed a miniature gamma probe – a device used to detect radiation in patients and guide surgery – which is inserted into a surgical port and can then be controlled by the clinician during the procedure. When used with molecularly-targeted imaging agents, Lightpoint's device enables the intra-operative detection of cancer in real time, supporting greater precision in the removal of tumours.

Telix and Lightpoint will evaluate the use of Telix's investigational prostate cancer single photon emission computed tomography (SPECT) imaging agent TLX599-CDx (^{99m}Tc-HYNIC-iPSMA) – together with Lightpoint's SENSEI[®] flexible laparoscopic gamma probe for intra-operative cancer detection. The ultimate objective of the clinical collaboration is to obtain marketing approval for use of TLX599-CDx in RGS, a new indication for prostate cancer.

Lightpoint Medical CEO, Graeme Smith said, "Surgeons currently have no reliable way to detect cancer intra-operatively, relying on sight or touch during an operation. As a result, cancer may be left behind or healthy tissue needlessly removed. The powerful combination of SENSEI[®] alongside Telix's groundbreaking molecularly-targeted imaging agents has the potential to create an extremely precise technique to help surgeons detect cancer that might not otherwise be found during surgery, or conversely, confirm the absence of disease to help surgeons retain healthy, functional tissue. I am extremely excited by the potential of this collaboration to transform surgical outcomes for patients across a range of major cancer types, starting with prostate cancer."

Telix CEO, Dr. Christian Behrenbruch added, "Bringing molecular imaging into the operating theatre is a key part of our portfolio strategy for urologic oncology, and the combination of Telix and Lightpoint technologies has potential to transform treatment options for patients with cancer. Together with the IRiS Alliance with Mauna Kea¹, this collaboration helps to reinforce Telix's position as a leader in developing advanced surgical technologies using highly targeted imaging techniques."

About TLX599-CDx

TLX599-CDx is an investigational product being developed by Telix to facilitate patient access to advanced prostate cancer imaging in countries where SPECT imaging is predominant in healthcare facilities. Whereas Telix's lead investigational product, Illuccix[®] for prostate cancer imaging, utilises positron emission tomography (PET), TLX599-CDx employs SPECT, a diagnostic imaging

¹ ASX disclosure 16/12/20.

technology that is more widely available in healthcare facilities throughout the world. In April 2021 Telix announced the launch of the NOBLE Registry², a global consortium of investigator-led studies exploring the clinical utility of TLX599-CDx, with the objective to generate data and facilitate the design of future formal registration clinical trials.

About Lightpoint Medical

Lightpoint Medical develops and markets miniaturized imaging and sensing tools for intra-operative cancer detection. The company is addressing the urgent medical challenge that despite technological advances in robotic platforms, surgeons lack the tools to accurately detect cancer intra-operatively. As a result, cancer is often left behind or more healthy tissue than needed is removed, increasing the need for adjuvant therapies, causing post-surgical complications, and escalating healthcare costs.

Lightpoint has a pipeline of miniaturized surgical tools in development with the first, SENSEI[®], recently approved for sale by regulators in the US, UK, EU, and Australia. The first commercial focus is prostate cancer surgery with a planned expansion into other solid tumor types.

For more information about the company visit: www.lightpointmedical.com; www.senseisurgical.com and follow us on [LinkedIn](#) and [Twitter](#).

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on [Twitter](#) (@TelixPharma) and [LinkedIn](#).

Telix's lead investigational product, illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,³ and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).⁴ Telix is also progressing marketing authorisation applications for illuccix[®] in the European Union⁵ and Canada.⁶ None of Telix's products have received a marketing authorisation in any jurisdiction.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

² ASX disclosure 19/04/21.

³ ASX disclosure 24/11/20.

⁴ ASX disclosure 14/04/21.

⁵ ASX disclosure 1/05/20.

⁶ ASX disclosure 16/12/20.